_____________________________________________________________________________________________ AI Early Detection
lung nodules, neurocritical findings, and infectious diseases earlier in the care pathway. Our aim is to empower clinicians to make quicker decisions, start treatment sooner, and streamline care coordination.
Qure. ai started in 2016 and now has teams in New York, London, Dubai, and Mumbai. You’ ll find our solutions in over 105 countries and more than 4,800 clinical sites. In the US, we have 19 FDA-cleared findings for lung and neurocritical conditions. Globally, we support 65 CE-certified findings and multiple national validations. In 2025, TIME named Qure. ai in its TIME100 Most Influential Companies for expanding access to diagnosis for high-burden diseases.
How does Qure. ai’ s AI support earlier lung cancer detection? Lung cancer is still the leading cause of cancer-related death in the US, and late diagnosis is a big reason why. Our lung portfolio helps by making detection, measurement, and patient management easier across different imaging types.
We provide an FDA-cleared suite of tools that clinicians can use as standalone tools or together in a single workflow. Our Chest X-ray AI spots lung nodules incidentally, while our CT-based tools handle measurement, quantification, and followup. When teams combine these tools, the benefits grow throughout the care pathway. We call this approach“ image to intervention”; supporting every step from detection to diagnosis and treatment coordination.
At University Hospitals Cleveland Medical Center in Ohio, our Chest X-ray AI acts as a second reader for radiologists. It helps with lung cancer surveillance during routine imaging, including emwergency department and pre-op scans. This approach works alongside CT screening programs that focus on high-risk groups.
In areas with limited CT screening, our Chest X-ray AI increases access to screening. One recent example is the CREATE study with AstraZeneca, presented at the 2025 European Society for Medical Oncology Congress. The study used routine chest X-rays to evaluate our AI-powered Lung Nodule Malignancy Score in Egypt, India, Indonesia, Mexico, and Turkey.
Out of more than 700 participants, our system identified 96 percent of confirmed lung cancer cases. Nearly 60 percent were in people who never smoked, including some under age 50. We detected 46 percent of cases at stages I to III, when treatment options are wider.
How does AI improve response in neurocritical care? In neurocritical care, timing is everything. Our head CT solution quickly triages intracranial hemorrhages and other critical findings. The system flags scans in minutes so care teams can respond right away.
Our solution helps emergency physicians, neurologists, and neurosurgeons by cutting down delays between imaging and intervention. It delivers 97 percent sensitivity for intracranial hemorrhage triage and enables 6 times more patients to be treated within 30 minutes of CT imaging.
Clinicians always make the final call. Our AI ensures urgent cases move up in the workflow, especially in busy settings where high volumes can slow things down.
How does Qure. ai support pharmaceutical trials? Every pharmaceutical partnership is unique. In some trials, we help identify patients with specific disease characteristics. In
americanhealthcareleader. com 21